
DealsNov 2, 2026, 04:11 PM
Theriva Biologics Sells Antibiotic Enzyme Portfolio to Biossil for $350K Upfront
AI Summary
Theriva Biologics, Inc. has completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), SYN-007, and SYN-006 (carbapenemase), to Biossil Labs Inc. Theriva received an upfront payment of $350,000 and is eligible for up to $91 million in regulatory and sales milestones, as well as low single-digit royalties on net product sales, subject to a $250 million cap. Biossil will now be responsible for the future development and commercialization of these assets.
Key Highlights
- Theriva Biologics sold its SYN-004 (ribaxamase) and related antibiotic-degrading enzyme portfolio to Biossil Labs Inc.
- Theriva received a $350,000 upfront payment at closing.
- Theriva is eligible for up to $3 million in regulatory milestones and up to $88 million in sales milestones.
- Theriva is also eligible to receive low single-digit royalties on net product sales, capped at $250 million.
- Biolssil will assume all future development and commercialization costs for the acquired portfolio.
- The deal includes assets related to SYN-004 (ribaxamase), SYN-007, and SYN-006 (carbapenemase).
Price Impact
More from TOVX